Replies to post #135105 on Biotech Values

[DewDiligence]

…value Celldex on the assumption of $400 million in sales of CDX-110 in 2020, discounted back at a 30% rate.

However, this DCF analysis is based on a 100% probability of technical success for the CDX-110 program. It’s somewhat odd, IMO, that the author of such an article does not try to quantify this metric.

[poorgradstudent]

Cldx:

As per usual, I do not believe that such peptide immunotherapeutics elicit a sufficient immune response. I would personally stay away from cldx even if that means I miss out on a phase iii success.

[biomaven0]

I'm cautious on their gliablastoma program - going to be hard to enroll. More optimistic on the breast cancer program though, although I haven't looked at it in a while. If that (breast) had been their only program I'd be an investor.

Peter